These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11907635)

  • 21. Advantages and pitfalls of combining device-based and pharmacologic therapies for the treatment of ventricular arrhythmias: observations from a tertiary referral center.
    Rajawat YS; Patel VV; Gerstenfeld EP; Nayak H; Marchlinski FE
    Pacing Clin Electrophysiol; 2004 Dec; 27(12):1670-81. PubMed ID: 15613132
    [No Abstract]   [Full Text] [Related]  

  • 22. [Drug therapy of ventricular arrhythmias - a contemporary perspective].
    Grönefeld GC; Hohnloser SH
    Dtsch Med Wochenschr; 2002 Oct; 127(43):2280-4. PubMed ID: 12397544
    [No Abstract]   [Full Text] [Related]  

  • 23. Dofetilide. UK 68, UK 68798, Tikosyn, Xelide.
    Drugs R D; 1999 Apr; 1(4):304-11. PubMed ID: 10566050
    [No Abstract]   [Full Text] [Related]  

  • 24. Azimilide dihydrochloride: a new class III anti-arrhythmic agent.
    Abrol R; Page RL
    Expert Opin Investig Drugs; 2000 Nov; 9(11):2705-15. PubMed ID: 11060832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Azimilide for atrial fibrillation: clinical trial results and implications.
    Pritchett EL; Marcello SR
    Card Electrophysiol Rev; 2003 Sep; 7(3):215-9. PubMed ID: 14739716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comment on generic anti-arrhythmic drugs.
    Mason G
    Cardiovasc J S Afr; 2002; 13(3):132. PubMed ID: 12193967
    [No Abstract]   [Full Text] [Related]  

  • 27. NerveCenter: FDA requirements for generic drug applications.
    Ann Neurol; 2010 Sep; 68(3):A11. PubMed ID: 20818779
    [No Abstract]   [Full Text] [Related]  

  • 28. Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification.
    Camm AJ; Pratt CM; Schwartz PJ; Al-Khalidi HR; Spyt MJ; Holroyde MJ; Karam R; Sonnenblick EH; Brum JM;
    Circulation; 2004 Mar; 109(8):990-6. PubMed ID: 14967728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sotalol for cardiac arrhythmias.
    Med Lett Drugs Ther; 1993 Apr; 35(893):27-8. PubMed ID: 8450806
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacologic management of arrhythmias.
    Bink-Boelkens MT
    Pediatr Cardiol; 2000; 21(6):508-15. PubMed ID: 11050274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myocardial repolarization and drugs. Impossibility to predict the dominance of anti-arrhythmic over pro-arrhythmic effects of drugs due to differential and ventricular electrical remodeling.
    Vos MA; Crijns HJ
    Anadolu Kardiyol Derg; 2001 Mar; 1(1):27-34. PubMed ID: 12122969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk prediction for adverse events during initiation of sotalol and dofetilide for the treatment of atrial fibrillation.
    Agusala K; Oesterle A; Kulkarni C; Caprio T; Subacius H; Passman R
    Pacing Clin Electrophysiol; 2015 Apr; 38(4):490-8. PubMed ID: 25626340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pure class III antiarrhythmic drugs: focus on dofetilide.
    Doshi SK; Singh BN
    J Cardiovasc Pharmacol Ther; 2000 Oct; 5(4):237-47. PubMed ID: 11150393
    [No Abstract]   [Full Text] [Related]  

  • 34. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular news.
    SoRelle R
    Circulation; 2001 Nov; 104(22):E9053-5. PubMed ID: 11723043
    [No Abstract]   [Full Text] [Related]  

  • 36. Dofetilide: a new class III antiarrhythmic agent.
    Roukoz H; Saliba W
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):9-19. PubMed ID: 17187453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Sotalol in treatment of pediatric severe (refractory) cardiac arrhythmias].
    Guo BJ; Li XM; Lu P; Qin DG; Wang L
    Zhonghua Er Ke Za Zhi; 2003 Oct; 41(10):780-1. PubMed ID: 14731366
    [No Abstract]   [Full Text] [Related]  

  • 38. Cumulative experience of azimilide-associated torsades de pointes ventricular tachycardia in the 19 clinical studies comprising the azimilide database.
    Pratt CM; Al-Khalidi HR; Brum JM; Holroyde MJ; Schwartz PJ; Marcello SR; Borggrefe M; Dorian P; Camm AJ;
    J Am Coll Cardiol; 2006 Aug; 48(3):471-7. PubMed ID: 16875971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and proarrhythmia of oral sotalol in pediatric patients.
    Pfammatter JP; Paul T; Lehmann C; Kallfelz HC
    J Am Coll Cardiol; 1995 Oct; 26(4):1002-7. PubMed ID: 7560592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dofetilide: a class III-specific antiarrhythmic agent.
    Kalus JS; Mauro VF
    Ann Pharmacother; 2000 Jan; 34(1):44-56. PubMed ID: 10669186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.